| abstract |
The present invention provides an immunogenic composition comprising: a. A directional adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptide alpha-helix; and b. A second peptide wrapped around a first peptide alpha-helix, a gastrin-17 peptide immunogen linked to an alpha-helix, which is one of the following: (i) a human comprising the amino acid sequence of SEQ ID 1 Gastrin-17, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably rhesus monkey or murine And / or (iii) a functionally active variant of either (i) or (ii) having 1, 2, 3 or 4 point mutations in the amino acid sequence of SEQ ID 2. The present invention further provides kits for preparing such immunogenic compositions, vaccines comprising such immunogenic compositions, and their use in medicine, eg for treating gastrin dependent diseases To do. [Selection figure] None |